Floatz logo

Epigallocatechin-3-Gallate

Relapsing-remitting Multiple Sclerosis

Charite University, Berlin, GermanyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

80 Active assets in the Relapsing-remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Natalizumab
Biogen
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Cladribine
Uppsala University
Phase 4BBB

View all 50 →

Same molecule, other indications

Epigallocatechin-3-Gallate is also rated in:

Duchenne muscular dystrophyDormant
B
Indicative ·
58 / 100
View asset →
hyperlipidemiaDormant
B
Indicative ·
57 / 100
View asset →
diabetes mellitusDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →